Epilepsy Clinical Trial
Official title:
A Study on the Non-face-to-face Care Using the Phone, Such as Counseling and Prescription, Temporarily Permitted During the COVID-19 Pandemic
NCT number | NCT05418257 |
Other study ID # | 2022-04-059-001 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | May 16, 2022 |
Est. completion date | May 31, 2023 |
Verified date | August 2023 |
Source | Samsung Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This is an observational study to confirm the non-inferior effectiveness on health outcomes of tele-counseling or tele-prescription, which was the first outpatient system applied to the actual medical sites in Korea during the coronavirus disease 2019 (COVID-19) pandemic. Researchers collect data using electronic medical records and questionnaires to patients and their caregivers who are continuously receiving outpatient treatment for epilepsy at a single center. The results of the study will be presented by comparing the health outcomes between the non-face-to-face care group and the usual care group.
Status | Completed |
Enrollment | 307 |
Est. completion date | May 31, 2023 |
Est. primary completion date | May 1, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: - Those who have received outpatient treatment for epilepsy at least twice from the Department of Neurology, Department of Pediatrics, Samsung Medical Center as of the date of participation in the study - Those who have been taking one or more anticonvulsants for 3 months or more as of the date of participation in the study - Those who have passed more than one month from the date of discharge from the hospital as of the date of participation in the study (However, hospitalization for examination only does not fall under this standard) Exclusion Criteria: - Those who have an experience of inpatient treatment within 1 month as of the date of participation in the study (However, hospitalization for examination only is not classified as hospitalization under this standard) - Those who have a record of visiting the emergency room within 1 month as of the date of participation in the study (However, visits that are not for epilepsy drug control are not classified as emergency room visits according to this standard) - Those who have been diagnosed with psychogenic non-epileptic seizure (PNES) through electroencephalogram (EEG) |
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Samsung Medical Center | Seoul | Gangnam-go |
Lead Sponsor | Collaborator |
---|---|
Samsung Medical Center |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | patient reported experience - 1) Reasons for using current care system (in-person versus telemedicine) | The reasons and obstacles for using current outpatient system will be collected with questionnaire. | both at the beginning of the study (month 0) and at the end of the study (month 6) | |
Other | patient reported experience - 2) Estimated time for outpatient visit | The average round-trip time from patient's house to hospital will be collected by questionnaire and then estimated. | at the end of the study (month 6) | |
Other | patient reported experience - 3) Estimated cost for outpatient visit | The opportunity cost will be collected by questionnaire and then estimated. | at the end of the study (month 6) | |
Other | patient reported experience - 4) Participants satisfaction | The satisfaction and willingness of participant using opposite outpatient system (in-person vs telemedicine) will be assessed by questionnaires. | at the end of the study (month 6) | |
Other | patient reported experience - 5) Caregiver satisfaction | The satisfaction and willingness of caregiver using opposite outpatient system (in-person vs telemedicine) will be assessed by questionnaires. | at the end of the study (month 6) | |
Primary | Seizure control - 1) Change from baseline seizure frequency at 6 months | It will be assessed by semi-structured questionnaire about categorizing seizure frequency.
: several times per day, 1~2 times per day, several times per week, 1~2 times per week, several times per month, 1~2 times per month, several times per year |
both at the beginning of the study (month 0) and at the end of the study (month 6) | |
Primary | Seizure control - 2) Change from baseline seizure type at 6 months | It will be collected by participants' free text description and then will be categorized to generalized, tonic, atonic, focal, absence and status epilepticus by physicians.
Successful seizure control is defined as no step up in category of seizure frequency and no manifestation of new-onset generalized, tonic/atonic seizure with fall or status epilepticus during study period. |
both at the beginning of the study (month 0) and at the end of the study (month 6) | |
Secondary | adherence to treatment - 1) Medication compliance | Medication compliance will be collected by self-report using Likert scale from 1 (worst) to 5 (best compliance as possible) | at the end of the study (month 6) | |
Secondary | adherence to treatment - 2) Outpatient visit compliance | Outpatient visit compliance will be assessed by counting complete in-person visit or telephone consultation and no-shows. | at the end of the study (month 6) | |
Secondary | Change from baseline adverse drugs reactions at 6 months | comparing change and new development of adverse drugs reactions between telemedicine group and usual care group | both at the beginning of the study (month 0) and at the end of the study (month 6) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04595513 -
Stopping TSC Onset and Progression 2: Epilepsy Prevention in TSC Infants
|
Phase 1/Phase 2 | |
Completed |
NCT02909387 -
Adapting Project UPLIFT for Blacks in Georgia
|
N/A | |
Completed |
NCT05552924 -
Self Acupressure on Fatigue and Sleep Quality in Epilepsy Patients
|
N/A | |
Terminated |
NCT01668654 -
Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects (>= 12 Years Old) With POS or LGS
|
Phase 3 | |
Not yet recruiting |
NCT05068323 -
Impact of Interictal Epileptiform Activity on Some Cognitive Domains in Newly Diagnosed Epileptic Patients
|
N/A | |
Completed |
NCT03994718 -
Creative Arts II Study
|
N/A | |
Recruiting |
NCT04076449 -
Quantitative Susceptibility Biomarker and Brain Structural Property for Cerebral Cavernous Malformation Related Epilepsy
|
||
Completed |
NCT00782249 -
Trial Comparing Different Stimulation Paradigms in Patients Treated With Vagus Nerve Stimulation for Refractory Epilepsy
|
N/A | |
Completed |
NCT03683381 -
App-based Intervention for Treating Insomnia Among Patients With Epilepsy
|
N/A | |
Recruiting |
NCT05101161 -
Neurofeedback Using Implanted Deep Brain Stimulation Electrodes
|
N/A | |
Active, not recruiting |
NCT06034353 -
Impact of Pharmacist-led Cognitive Behavioral Intervention on Adherence and Quality of Life of Epileptic Patients
|
N/A | |
Recruiting |
NCT05769933 -
Bridging Gaps in the Neuroimaging Puzzle: New Ways to Image Brain Anatomy and Function in Health and Disease Using Electroencephalography and 7 Tesla Magnetic Resonance Imaging
|
||
Not yet recruiting |
NCT06408428 -
Glioma Intraoperative MicroElectroCorticoGraphy
|
N/A | |
Not yet recruiting |
NCT05559060 -
Comorbidities of Epilepsy(Cognitive and Psychiatric Dysfunction)
|
||
Completed |
NCT02977208 -
Impact of Polymorphisms of OCT2 and OCTN1 on the Kinetic Disposition of Gabapentin in Patients Undergoing Chronic Use
|
Phase 4 | |
Completed |
NCT02646631 -
Behavioral and Educational Tools to Improve Epilepsy Care
|
N/A | |
Completed |
NCT02952456 -
Phenomenological Approach of Epilepsy in Patients With Epilepsy
|
||
Recruiting |
NCT02539134 -
TAK-935 Multiple Rising Dose Study in Healthy Participants
|
Phase 1 | |
Completed |
NCT02491073 -
Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements for Subjects Treated With Eslicarbazeine Acetate (ESL)
|
N/A | |
Terminated |
NCT02757547 -
Transcranial Magnetic Stimulation for Epilepsy
|
N/A |